Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib

Massimo Breccia, Fabio Efficace, Alessandra Iurlo, Luigiana Luciano, Elisabetta Abruzzese, Antonella Gozzini, Patrizia Pregno, Mario Tiribelli, Gianantonio Rosti, Giorgio Minotti

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in chronic myeloid leukemia (CML), many patients develop intolerance and discontinue therapy in the long-term. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI, ponatinib, have added opportunities but also complexity in the settings of CML treatment. Areas covered: Different definitions of intolerance have been used through several clinical trials, making the published data non homogenous. In most cases, only the severity of acute adverse events (AEs), graded by conventional scales such as Common Terminology Criteria for Adverse Events, was reported. Limited attention to long-term events or more in general, to the impact of AEs on patient quality of life (QoL), remains a problem. Ponatinib is active against all BCR-ABL1 mutants, including T315I, and is widely used to treat patients who developed resistance to other TKIs in any CML phase; however, only limited data is available on the possible role of ponatinib for intolerant patients. Expert opinion: We review the different definitions of intolerance used in sponsored trials and in clinical practice, and we discuss how such definitions impact on the management of AEs. We summarize how to evaluate QoL during treatment with TKIs and how to include ponatinib among possible option for intolerant patients.

Original languageEnglish
Pages (from-to)623-628
Number of pages6
JournalExpert Opinion on Drug Safety
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 3 2018

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Quality of Life
Clinical Trials
Leukemia, Myeloid, Chronic Phase
Expert Testimony
Terminology
Therapeutics
ponatinib

Keywords

  • Chronic myeloid leukemia
  • intolerance
  • QoL
  • safety
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia : the possible role of ponatinib. / Breccia, Massimo; Efficace, Fabio; Iurlo, Alessandra; Luciano, Luigiana; Abruzzese, Elisabetta; Gozzini, Antonella; Pregno, Patrizia; Tiribelli, Mario; Rosti, Gianantonio; Minotti, Giorgio.

In: Expert Opinion on Drug Safety, Vol. 17, No. 6, 03.06.2018, p. 623-628.

Research output: Contribution to journalReview article

Breccia, M, Efficace, F, Iurlo, A, Luciano, L, Abruzzese, E, Gozzini, A, Pregno, P, Tiribelli, M, Rosti, G & Minotti, G 2018, 'Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib', Expert Opinion on Drug Safety, vol. 17, no. 6, pp. 623-628. https://doi.org/10.1080/14740338.2018.1480719
Breccia, Massimo ; Efficace, Fabio ; Iurlo, Alessandra ; Luciano, Luigiana ; Abruzzese, Elisabetta ; Gozzini, Antonella ; Pregno, Patrizia ; Tiribelli, Mario ; Rosti, Gianantonio ; Minotti, Giorgio. / Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia : the possible role of ponatinib. In: Expert Opinion on Drug Safety. 2018 ; Vol. 17, No. 6. pp. 623-628.
@article{8a1af86dee0645bf809a783f72c63d77,
title = "Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib",
abstract = "Introduction: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in chronic myeloid leukemia (CML), many patients develop intolerance and discontinue therapy in the long-term. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI, ponatinib, have added opportunities but also complexity in the settings of CML treatment. Areas covered: Different definitions of intolerance have been used through several clinical trials, making the published data non homogenous. In most cases, only the severity of acute adverse events (AEs), graded by conventional scales such as Common Terminology Criteria for Adverse Events, was reported. Limited attention to long-term events or more in general, to the impact of AEs on patient quality of life (QoL), remains a problem. Ponatinib is active against all BCR-ABL1 mutants, including T315I, and is widely used to treat patients who developed resistance to other TKIs in any CML phase; however, only limited data is available on the possible role of ponatinib for intolerant patients. Expert opinion: We review the different definitions of intolerance used in sponsored trials and in clinical practice, and we discuss how such definitions impact on the management of AEs. We summarize how to evaluate QoL during treatment with TKIs and how to include ponatinib among possible option for intolerant patients.",
keywords = "Chronic myeloid leukemia, intolerance, QoL, safety, tyrosine kinase inhibitors",
author = "Massimo Breccia and Fabio Efficace and Alessandra Iurlo and Luigiana Luciano and Elisabetta Abruzzese and Antonella Gozzini and Patrizia Pregno and Mario Tiribelli and Gianantonio Rosti and Giorgio Minotti",
year = "2018",
month = "6",
day = "3",
doi = "10.1080/14740338.2018.1480719",
language = "English",
volume = "17",
pages = "623--628",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia

T2 - the possible role of ponatinib

AU - Breccia, Massimo

AU - Efficace, Fabio

AU - Iurlo, Alessandra

AU - Luciano, Luigiana

AU - Abruzzese, Elisabetta

AU - Gozzini, Antonella

AU - Pregno, Patrizia

AU - Tiribelli, Mario

AU - Rosti, Gianantonio

AU - Minotti, Giorgio

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Introduction: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in chronic myeloid leukemia (CML), many patients develop intolerance and discontinue therapy in the long-term. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI, ponatinib, have added opportunities but also complexity in the settings of CML treatment. Areas covered: Different definitions of intolerance have been used through several clinical trials, making the published data non homogenous. In most cases, only the severity of acute adverse events (AEs), graded by conventional scales such as Common Terminology Criteria for Adverse Events, was reported. Limited attention to long-term events or more in general, to the impact of AEs on patient quality of life (QoL), remains a problem. Ponatinib is active against all BCR-ABL1 mutants, including T315I, and is widely used to treat patients who developed resistance to other TKIs in any CML phase; however, only limited data is available on the possible role of ponatinib for intolerant patients. Expert opinion: We review the different definitions of intolerance used in sponsored trials and in clinical practice, and we discuss how such definitions impact on the management of AEs. We summarize how to evaluate QoL during treatment with TKIs and how to include ponatinib among possible option for intolerant patients.

AB - Introduction: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in chronic myeloid leukemia (CML), many patients develop intolerance and discontinue therapy in the long-term. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI, ponatinib, have added opportunities but also complexity in the settings of CML treatment. Areas covered: Different definitions of intolerance have been used through several clinical trials, making the published data non homogenous. In most cases, only the severity of acute adverse events (AEs), graded by conventional scales such as Common Terminology Criteria for Adverse Events, was reported. Limited attention to long-term events or more in general, to the impact of AEs on patient quality of life (QoL), remains a problem. Ponatinib is active against all BCR-ABL1 mutants, including T315I, and is widely used to treat patients who developed resistance to other TKIs in any CML phase; however, only limited data is available on the possible role of ponatinib for intolerant patients. Expert opinion: We review the different definitions of intolerance used in sponsored trials and in clinical practice, and we discuss how such definitions impact on the management of AEs. We summarize how to evaluate QoL during treatment with TKIs and how to include ponatinib among possible option for intolerant patients.

KW - Chronic myeloid leukemia

KW - intolerance

KW - QoL

KW - safety

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85048283098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048283098&partnerID=8YFLogxK

U2 - 10.1080/14740338.2018.1480719

DO - 10.1080/14740338.2018.1480719

M3 - Review article

AN - SCOPUS:85048283098

VL - 17

SP - 623

EP - 628

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -